Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis.

Refractory ascites is a common complication of cirrhosis of the liver. Build-up of fluid causes difficulty in breathing, fatigue, nausea, poor appetite, acid reflux, abdominal pain and infection.

As scar tissue replaces healthy liver tissue, the liver can no longer function properly. Ascites is the accumulation of fluid in the abdominal cavity, causing swelling and discomfort. It’s a common ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of ...

Ascites is a buildup of fluid in the abdomen. It can happen when the liver is not working properly. Fluid fills the space between the organs and the abdominal lining, leading to swelling and pain.

Ghent, Belgium – 28 December 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

HERNIA is known to be more frequent among patients with cirrhosis of the liver, especially with ascites, than among those without liver disease. Chapman et al. 1 reported a rate of 10 per cent in 58 ...